Kristina Jankovic, MD· @JankovicK · X·· 1 天前评分70
正文 · 原文
#ESMO26 | postMONARCH – Final OS
Abemaciclib + fulvestrant 🆚 placebo + fulvestrant after prior CDK4/6i in HR+/HER2− advanced #BreastCancer :
🔹 mOS 32.1 🆚 24.6 mo (HR 0.80; p=0.11) - numeric benefit, not statistically significant.
simultaneously published in @Annals_Oncology 👇
🔗 http://annalsofoncology.org/article/S0923-7534%2826%2908075-0/
#bcsm @myESMO @OncoAlert
38 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.org来源：Kristina Jankovic, MD · x.com